Source: Reuters Health
Thursday, November 20, 2008
Chemotherapy-naive patients with non-small cell lung cancer (NSCLC) along with epidermal growth factor receptor mutations of the tyrosine kinase domain have greater responses to gefitinib than those who have received chemotherapy, according to Taiwanese researchers.
Full Story